Navitus updates

PBM 101: Understanding Spread Pricing and Its Impact on Plan Costs

Read More
Part D Star Ratings Adherence Measures: Enabling Strategic and Focused Support for High-risk Beneficiaries Through the Reporting and Intervention for Stars Excellence (RISE) Program

Read More
PBM 101: How to Evaluate Your PBM

Read More
Introducing NavitusClear with Costco® Cost Plus Model

Read More
PBM 101: Understanding Transparency for Better Pharmacy Benefits

Read More
Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Read More
Navigating the Drug Supply Chain: What You Need to Know

Read More
Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Read More
PBM 101: Why the Model Matters

Read More
Associate Resource Group Spotlight: Green Team

Read More
PBM 101: The Three PBM Business Models

Read More
An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

Read More
Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings

Read More
Pass-Through PBM Partnership Value

Read More
Achieving Outstanding Results with Tailored Network Strategies

Read More
Breaking Through Barriers with Value-Based Plan Design

Read More
Finding a Solution to Lower Prescription Drug Costs

Read More
Empowered by Strategic Opportunities and Service Excellence

Read More